SCHEMBL975555

SCHEMBL975555

Nc1cc(-c2ccsc2)ccc1NC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.56
HDAC1 Q13547 3/20 0.49
ACMSD Q8TDX5 1/20 0.48
VCP P55072 1/20 0.46
ABCB1 P08183 1/20 0.42
IKBKB O14920 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CHEK2 O96017 2/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
ERN1 O75460 1/20 0.41
PTPRF P10586 1/20 0.41
PTPN1 P18031 1/20 0.41
P2RY14 Q15391 1/20 0.40
AAK1 Q2M2I8 1/20 0.40
BACE1 P56817 1/20 0.40
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30474853 0.80 AAK1 (0.48) KCNH2HDAC1ACMSDVCPABCB1
SCHEMBL5868760 0.80 AAK1 (0.48) KCNH2HDAC1ACMSDVCPABCB1
SCHEMBL651882 0.79 HDAC1 (0.57) HDAC1ABCB1IKBKBALDH1A1MAPT
SCHEMBL4126494 0.79 HDAC1 (0.58) KCNH2HDAC1MAPTCHEK2PPARG
SCHEMBL7467565 0.78 AAK1 (0.61) HDAC1ABCB1AAK1
SCHEMBL13735115 0.76 HDAC1 (0.55) HDAC1ABCB1
SCHEMBL976915 0.75 HDAC1 (0.60) KCNH2HDAC1
SCHEMBL4579995 0.75 HDAC1 (0.75) KCNH2HDAC1MAPTHDAC6
SCHEMBL20163155 0.73 HDAC2 (0.58) HDAC1ABCB1ERN1P2RY14CNR1
SCHEMBL14775717 0.73 CCNE2 (0.43) HDAC1IKBKBMAPTPTPRFPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2023924-B1 ARYL-FUSED SPIROCYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2016-08-03 EP disclosed
US-20130131041-A1 SPIROCYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2013-05-23 US disclosed
US-8440830-B2 Tetrahydro-fused pyridines as histone deacetylase inhibitors 4SC AG (DE) 2013-05-14 US disclosed
EP-1991226-B1 INHIBITORS OF HISTONE DEACETYLASE MERCK SHARP & DOHME (US) 2013-03-20 EP disclosed
EP-2197552-B1 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2012-11-21 EP disclosed
US-8168658-B2 Inhibitors of histone deacetylase MERCK SHARP & DOHME CORP. (US) 2012-05-01 US disclosed
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2011-01-27 US disclosed
EP-2197552-A2 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2010-06-23 EP disclosed
US-20090209566-A1 Spirocyclic Compounds MERCK SHARP & DOHME LLC 2009-08-20 US disclosed
EP-1954698-B1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS MERCK & CO INC (US) 2009-06-24 EP disclosed
US-20090069250-A1 Inhibitors of Histone Deacetylase MERCK SHARP & DOHME LLC 2009-03-12 US disclosed
EP-2023924-A2 ARYL-FUSED SPIROCYCLIC COMPOUNDS Merck & Co., Inc. (US) 2009-02-18 EP disclosed
CN-101312976-A Spirocyclic compounds as hdac inhibitors MERCK & CO INC (US) 2008-11-26 CN disclosed
EP-1991226-A2 INHIBITORS OF HISTONE DEACETYLASE Merck & Co., Inc. (US) 2008-11-19 EP disclosed
EP-1954698-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS Merck & Co., Inc. (US) 2008-08-13 EP disclosed
WO-2007136605-A2 ARYL-FUSED SPIROCYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 WO disclosed
WO-2007100657-A2 INHIBITORS OF HISTONE DEACETYLASE MERCK & CO., INC. (US) 2007-09-07 WO disclosed
WO-2007061978-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS MERCK & CO., INC. (US) 2007-05-31 WO disclosed
WO-2007061880-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS MERCK & CO., INC. (US) 2007-05-31 WO disclosed
US-20070117824-A1 Spirocyclic compounds MERCK SHARP & DOHME LLC 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC3 KCNH2 2951/4885HDAC1 1/4885ACMSD 3595/4885
US-20090069250-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC6 KCNH2 3411/4885HDAC1 1/4885ACMSD 4235/4885
US-20090209566-A1 Spirocyclic Compounds NR1H2, RORA, NR2E3 KCNH2 2541/4885HDAC1 12/4885ACMSD 4257/4885
US-20070117824-A1 Spirocyclic compounds BRDT, TXNRD3, HDAC1 KCNH2 2416/4885HDAC1 3/4885ACMSD 4512/4885
US-20130131041-A1 SPIROCYCLIC COMPOUNDS BRDT, TXNRD3, HDAC1 KCNH2 2416/4885HDAC1 3/4885ACMSD 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.